A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

NCT04033354 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

537

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Non Small Cell Lung Cancer

Interventions

DRUG: HLX10
DRUG: carboplatin and nab paclitaxel
DRUG: Placebo

Sponsor

Shanghai Henlius Biotech